ClinicalTrials.gov
ClinicalTrials.gov Menu

Velocimetric Study of Temporal Arteries in Patients With Horton Disease Using Scan-Doppler (VELHOR)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03360162
Recruitment Status : Recruiting
First Posted : December 4, 2017
Last Update Posted : December 4, 2017
Sponsor:
Information provided by (Responsible Party):
University Hospital, Brest

Brief Summary:
The use of ultrasonography in detecting giant cell arteritis ( GCA) is emerging. Currently, temporal biopsy is the gold standard to diagnose GCA but studies have shown the interest to use B mode ultrasonography. However, until now, the study of velocities in GCA have not been yet performed.

Condition or disease
Horton Disease

Study Type : Observational
Estimated Enrollment : 42 participants
Observational Model: Cohort
Time Perspective: Retrospective
Official Title: Velocimetric Study of Temporal Arteries in Patients With Horton Disease Using Scan-Doppler
Actual Study Start Date : November 2, 2017
Estimated Primary Completion Date : December 10, 2017
Estimated Study Completion Date : December 10, 2017





Primary Outcome Measures :
  1. Velocimetric Study of Temporal Arteries in Patients With Horton Disease Using Scan-Doppler [ Time Frame: 2 months ]
    velocimetric temporal arterial study in giant arteritis


Secondary Outcome Measures :
  1. evaluation of the halo sign in giant arteritis using B mode ultrasonography [ Time Frame: 2 months ]
    presence or absence of the halo sign in giant arteritis patients



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   55 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Sampling Method:   Probability Sample
Study Population
all patients aged more than 55 years old who are suspected of giant arteritis
Criteria

Inclusion Criteria:

  • patients with suspicious giant arteritis

Exclusion Criteria:

  • patients who have already been treated or diagnosed for giant arteritis

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03360162


Contacts
Contact: Sandrine Jousse-Joulin, MD +33 2 98 34 72 64 sandrine.jousse@chu-brest.fr

Locations
France
CHRU de Brest Recruiting
Brest, France, 29609
Contact: Sandrine Jousse-Joulin       sandrine.jousse@chu-brest.fr   
Sponsors and Collaborators
University Hospital, Brest

Responsible Party: University Hospital, Brest
ClinicalTrials.gov Identifier: NCT03360162     History of Changes
Other Study ID Numbers: VELHOR ( 29BRC17.0227)
First Posted: December 4, 2017    Key Record Dates
Last Update Posted: December 4, 2017
Last Verified: November 2017

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Vasculitis, Central Nervous System
Vasculitis
Giant Cell Arteritis
Polymyalgia Rheumatica
Autoimmune Diseases of the Nervous System
Nervous System Diseases
Cerebrovascular Disorders
Brain Diseases
Central Nervous System Diseases
Vascular Diseases
Cardiovascular Diseases
Arteritis
Skin Diseases, Vascular
Skin Diseases
Autoimmune Diseases
Immune System Diseases
Muscular Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Connective Tissue Diseases